Case Reports in Medicine years, and shows a strong female preponderance [3]. Our patient, a previously healthy, young female, was experiencing typical symptoms like recurrent cough and shortness of breath for 5 years. The prolonged history should have alerted treating physicians of an underlying pathology. However, the non-speciﬁc symptoms might be attributed to the delay in arriving at a precise diagnosis. Initially, she was misdiagnosed as bronchial asthma and was prescribed Salbutamol inhaler which seem to alleviate the symptoms for a brief period of time. On presentation to our hospital, a simple non-invasive test led to a series of events conﬁrming the diagnosis of CBPB. About 80% of CBPB occur in adults, and can occur at any age between birth and seventy years [4]. Unlike PB, CBPB shows a slight male preponderance and is common among smokers [4]. Interestingly, our patient was a teenager, nonsmoker female patient. Symptoms in CBPB are likely to seem like an upper respiratory infection, but recurrent, persistent symptoms require investigations. In CBPB, chest radiography is usually helpful and typically shows a well-demarcated peripheral or midlung mass with no deﬁnite lobar predominance [4]. In our case also, a well- circumscribed lesion was seen in the right middle lobe which was conﬁrmed on chest CT scan showing a mixed solid and cystic lesion with variable contrast enhancement and a necrotic center with no evidence of involvement of pleura or mediastinum, which would have otherwise indicated metastasis. Immunohistochemistry plays a vital role in the diagnosis of CBPB. Each component can be clearly distinguished with each other when a combination of both epithelial and mes- enchymal markers is used [4]. In our case, complete excision biopsy was done, and a panel of immunohistochemical markers conﬁrmed the biphasic pattern comprising epithe- lial and malignant mesenchymal components consistent with CBPB. Surgical resection is the mainstay of treatment for the patients with PB. A number of cases of surgical approach with curative intent have been reported including an interest- ing case with a 24-year complete remission postsurgery [5]. Literature regarding the eﬃcacy of adjuvant chemother- apy and radiotherapy is scarce. The vague role of chemother- apy in the adjuvant setting is probably due to rarity of this malignancy and seems to be individualized in reported cases. Various combinations of chemotherapeutic drugs have been tried as neoadjuvant and adjuvant treatment. However, several case reports document the use of platinum-based adjuvant treatment [3, 4]. Our patient received 6 cycles of the ICE protocol com- prising of ifosfamide, carboplatin, and etoposide. Reevalua- tion was done by CT scan of chest after 3rd and 6th cycles of chemotherapy which showed no evidence of recurrence. The patient experienced acute emesis postchemotherapy during the ﬁrst 3 cycles. Prophylactic granulocyte colony- stimulating factor (G-CSF) was given for 1 week from day 5 after each cycle. The patient had not been considered as a candidate for radiotherapy due to the presence of poor prognostic features, in addition to lack of suﬃcient data supporting the deﬁnite role of radiation in the adjuvant 3 setting. The patient is on ongoing 3 monthly follow up with complete remission. Reevaluation CT scans will be done, and the patient is advised to seek immediate medical care in case of appearance of previous or novel symptoms. Although, several individual case reports of long-term survival have been documented, the overall prognosis of this rare malignancy is poor, and two-thirds of patients die within 2 years of diagnosis [5]. In one survey of 83 cases, the mean survival of approximately 33 months was reported for the patients who underwent surgery and achieved negative margins [5]. The factors contributing to the unfavorable prognosis are the biphasic type, tumor recurrence, metastatic disease on presentation, tumor size over 5 cm, and frequent lymph node involvement [1, 2]. In our case, the decision to start adjuvant treatment was based on the presence of two important prognostic factors, namely, the large size of the tumor on presentation (around 11 cm) and biphasic pattern of the disease. Despite not receiving any postoperative radiotherapy, the patient continues to be in remission until last followup. In conclusion, whether adjuvant treatment plays a role in the remission or not is a debatable issue, this case suggests a wait- and- watch approach when platinum-based chemotherapy is given as an adjuvant in the management of PB. Although a large series of case studies is required to further analyze and establish a framework for the deﬁnite role of adjuvant chemotherapy, and owing to the rarity of this malignancy, adjuvant management following surgery may be based on individual cases depending on the histopathology and stage of the tumor. Consent This case report is being submitted after written consent was signed by the patient. Conﬂict of Interests The authors declared that there is no conﬂict of interests. References [1] C. S. Cutler, R. P. Michel, M. Yassa, and A. Langleben, “Pulmonary blastoma: case report of a patient with a 7-year remission and review of chemotherapy experience in the world literature,” Cancer, vol. 82, no. 3, pp. 462–467, 1998. [2] M. N. Koss, L. Hochholzer, and T. O’Leary, “Pulmonary blastomas,” Cancer, vol. 67, no. 9, pp. 2368–2381, 1991. [3] J. Robert, J. C. Pache, Y. Seium, M. De Perrot, and A. Spiliopoulos, “Pulmonary blastoma: report of ﬁve cases and identiﬁcation of clinical features suggestive of the disease,” European Journal of Cardio-thoracic Surgery, vol. 22, no. 5, pp. 708–711, 2002. [4] R. I. Walker, K. Suvarna, and S. Matthews, “Pulmonary blastoma: presentation of two atypical cases and review of the literature,” British Journal of Radiology, vol. 78, no. 929, pp. 437–440, 2005.